Screener Summaries Updates Institutions Sign In More Updates › Other Events › CPRX Other Events · Jun 30, 2026
Catalyst reports positive topline results from two-part Phase 1 study of AGAMREE CPRX Catalyst Pharmaceuticals, Inc.
On June 30, 2026, Catalyst Pharmaceuticals announced topline results from a two-part Phase 1 clinical study of AGAMREE (vamorolone). The company operates in the pharmaceutical industry and develops treatments for rare diseases.
More from Catalyst Pharmaceuticals, Inc. All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
